NovoCure (NVCR) Cash & Current Investments (2014 - 2026)

NovoCure has disclosed Cash & Current Investments across 13 years of filings, most recently posting $432.0 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $432.0 million, down 53.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $432.0 million (down 53.5% YoY), and the FY2025 annual result was $103.4 million, down 89.23% from the prior year.
• Cash & Current Investments came in at $432.0 million for Q1 2026 at NovoCure, up from $103.4 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $969.4 million in Q4 2022 to a low of $103.4 million in Q4 2025.
• The 5-year median for Cash & Current Investments is $432.0 million (2026), against an average of $555.8 million.
• Across the five-year window, Cash & Current Investments soared 366.22% in 2024 and sank 89.23% in 2025, its largest moves.
• NovoCure's Cash & Current Investments stood at $969.4 million in 2022, then decreased by 6.07% to $910.6 million in 2023, then grew by 5.41% to $959.9 million in 2024, then tumbled by 89.23% to $103.4 million in 2025, then soared by 317.84% to $432.0 million in 2026.
• The last three Cash & Current Investments figures came in at $432.0 million (Q1 2026), $103.4 million (Q4 2025), and $344.6 million (Q3 2025), per Business Quant data.